Dr. Eric D. Nudleman, M.D., PH.D.
Ophthalmology (Ophthalmology Physician)
200 W Arbor Dr
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 896
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A131592 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 896
- Services billed
- 13,625
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Imaging of retina | 2,026 | 888 |
| Established patient complete exam of visual system | 1,809 | 899 |
| Injection of drug into eye | 699 | 136 |
| Compounded drug, not otherwise classified | 560 | 98 |
| Injection, aflibercept, 1 mg | 244 | 22 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 68 | 11 |
| Exam of visual field with extended testing | 23 | 23 |
| Photography of the retina | 12 | 11 |
| New patient complete exam of visual system | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in San Diego, CA | 25 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in San Diego, CA | 16 |
| Latanoprost Other prescribers in San Diego, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 31 payments worth $73,981 in total to this clinician.
| Alcon Vision LLC | $29,612 |
|---|---|
| Boehringer Ingelheim International GmbH | $24,295 |
| Genentech USA, Inc. | $18,146 |
| AbbVie Inc. | $1,700 |
| Bausch & Lomb Americas Inc. | $140 |
| Ocular Therapeutix, Inc. | $65.72 |
| Astellas Pharma US Inc | $22.23 |
| Consulting Fee | $48,620 |
|---|---|
| Travel and Lodging | $17,527 |
| Compensation for services other than consulting (speaking, faculty) | $6,720 |
| Food and Beverage | $1,114 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alcon Vision LLC Nov 20, 2025 | Consulting Fee Constellation; UNITY · Ophthalmology | $15,000 |
| Alcon Vision LLC Nov 20, 2025 | Consulting Fee NGENUITY; UNITY · Ophthalmology | $11,000 |
| Genentech USA, Inc. May 17, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $10,125 |
| Boehringer Ingelheim International GmbH Mar 17, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $9,500 |
| Genentech USA, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) Vabysmo · Immunology and Ophthalmology | $6,720 |
| Boehringer Ingelheim International GmbH Feb 27, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $6,000 |
| Boehringer Ingelheim International GmbH Feb 27, 2025 | Consulting Fee | $4,245 |
| Boehringer Ingelheim International GmbH Mar 17, 2025 | Consulting Fee | $3,800 |
| Alcon Vision LLC Dec 18, 2025 | Consulting Fee UNITY · Ophthalmology | $2,000 |
| AbbVie Inc. Jan 23, 2025 | Consulting Fee | $1,700 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alcon Vision LLC Dec 18, 2025 | Consulting Fee UNITY · Ophthalmology | $2,000 |
| Alcon Vision LLC Nov 20, 2025 | Consulting Fee Constellation; UNITY · Ophthalmology | $15,000 |
| Alcon Vision LLC Nov 20, 2025 | Consulting Fee NGENUITY; UNITY · Ophthalmology | $11,000 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging Alcon Greishaber Finesse; Constellation; UNITY · Ophthalmology · travel to Fort Worth, TX · in-kind | $419 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging Constellation; UNITY · Ophthalmology · travel to Fort Worth, TX · in-kind | $388 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging NGENUITY; Finesse Sharkskin; Constellation · Ophthalmology · travel to Fort Worth, TX · in-kind | $273 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging Finesse Sharkskin; NGENUITY; UNITY · Ophthalmology · travel to Fort Worth, TX · in-kind | $225 |
| Genentech USA, Inc. May 17, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $10,125 |
| Genentech USA, Inc. May 17, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Dallas, TX · in-kind | $341 |
| Genentech USA, Inc. May 17, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Dallas, TX · in-kind | $293 |
| Genentech USA, Inc. May 17, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Dallas, TX · in-kind | $88.85 |
| Boehringer Ingelheim International GmbH Mar 17, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $9,500 |
| Boehringer Ingelheim International GmbH Mar 17, 2025 | Consulting Fee | $3,800 |
| Boehringer Ingelheim International GmbH Feb 27, 2025 | Travel and Lodging travel to Mainz, Germany · in-kind | $6,000 |
| Boehringer Ingelheim International GmbH Feb 27, 2025 | Consulting Fee | $4,245 |
| AbbVie Inc. Jan 23, 2025 | Consulting Fee | $1,700 |
| Boehringer Ingelheim International GmbH Jan 14, 2025 | Consulting Fee | $750 |
| Genentech USA, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) Vabysmo · Immunology and Ophthalmology | $6,720 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $14,869 in research payments for these studies, mostly to the institutions running them.
- Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
AbbVie Inc. · Enrolling by invitation · NCT03999801 - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
AbbVie Inc. - Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04515524 - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.